- Home
- NKSH vs ACIU Comparison
NKSH vs ACIU Comparison
Compare NKSH & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- ACIU
- Stock Information
- Founded
- NKSH 1891
- ACIU 2003
- Country
- NKSH United States
- ACIU Switzerland
- Employees
- NKSH N/A
- ACIU N/A
- Industry
- NKSH Major Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- ACIU Health Care
- Exchange
- NKSH Nasdaq
- ACIU Nasdaq
- Market Cap
- NKSH 185.2M
- ACIU 213.3M
- IPO Year
- NKSH N/A
- ACIU 2016
- Fundamental
- Price
- NKSH $30.09
- ACIU $3.29
- Analyst Decision
- NKSH Strong Buy
- ACIU Strong Buy
- Analyst Count
- NKSH 1
- ACIU 2
- Target Price
- NKSH $38.00
- ACIU $10.00
- AVG Volume (30 Days)
- NKSH 8.6K
- ACIU 402.9K
- Earning Date
- NKSH 10-23-2025
- ACIU 11-04-2025
- Dividend Yield
- NKSH 5.07%
- ACIU N/A
- EPS Growth
- NKSH 41.83
- ACIU N/A
- EPS
- NKSH 2.04
- ACIU N/A
- Revenue
- NKSH $51,980,000.00
- ACIU $5,482,957.00
- Revenue This Year
- NKSH $2.95
- ACIU N/A
- Revenue Next Year
- NKSH $9.97
- ACIU $1,022.98
- P/E Ratio
- NKSH $14.59
- ACIU N/A
- Revenue Growth
- NKSH 19.64
- ACIU N/A
- 52 Week Low
- NKSH $23.75
- ACIU $1.43
- 52 Week High
- NKSH $32.39
- ACIU $4.00
- Technical
- Relative Strength Index (RSI)
- NKSH 58.05
- ACIU 52.53
- Support Level
- NKSH $27.00
- ACIU $3.20
- Resistance Level
- NKSH $29.23
- ACIU $3.70
- Average True Range (ATR)
- NKSH 0.73
- ACIU 0.41
- MACD
- NKSH 0.19
- ACIU -0.01
- Stochastic Oscillator
- NKSH 100.00
- ACIU 49.33
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.